NIH RECOVER

  • NIH officials discuss agency’s Long COVID clinical trials, respond to critiques

    NIH officials discuss agency’s Long COVID clinical trials, respond to critiques

    “We understand the frustration and respect it completely,” said NIAID program officer and TLC leader Joseph Breen, when asked about the more than a year that’s gone between RECOVER-TLC trials’ announcement and enrolling participants.

  • Live blog: RECOVER-TLC third annual workshop shares updates on Long COVID clinical trials

    Live blog: RECOVER-TLC third annual workshop shares updates on Long COVID clinical trials

    Leading Long COVID scientists, government officials, and advocates are meeting today and tomorrow in Bethesda, Maryland for the third annual RECOVER-Treating Long COVID (TLC) workshop, hosted by the National Institutes of Health (NIH) and Foundation for the National Institutes of Health (FNIH). At a hotel near the NIH campus, attendees will hear updates on the…

  • Research updates, October 27

    Research updates, October 27

    Low-dose prednisolone may temporarily reduce some “symptom severity” of Long COVID, according to a new study in eClinicalMedicine. German researchers evaluated the drug, a corticosteroid that reduces inflammation and is used to treat a broad range of conditions, alongside some B vitamins, in the phase 3 clinical trial.

  • Research updates, September 1

    Research updates, September 1

    People with Long COVID are at a higher risk for cardiovascular, renal, and pulmonary (CRP) outcomes, according to a large observational study published in Journal of the American Heart Association. The study was a retrospective study and assessed more than 2.6 million people who developed COVID-19, comparing about 158,000 people who had been diagnosed with…

  • Research updates, August 11

    Research updates, August 11

    COVID-19 can reactivate dormant viruses in the body, confirms new research in Nature.

  • Research updates, July 21

    Research updates, July 21

    The dementia drug donepezil helped decrease fatigue in a subset of people with Long COVID, according to a study published in Frontiers in Pharmacology. In the complex study, which also included testing in mice, Japanese researchers found a majority of people with Long COVID in the cohort had reactivated human herpes virus 6 (HHV-6), which produced…

  • Research updates, July 7

    Research updates, July 7

    An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.

  • Research updates, June 9

    Research updates, June 9

    A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.

  • Why are RECOVER’s first round of Long COVID clinical trials failing?

    Why are RECOVER’s first round of Long COVID clinical trials failing?

    The U.S.’s flagship Long COVID research program has received over a billion dollars in funding and had years of input from people with the disease. But its first round of clinical trials are failing, at least in the results out so far.

  • RECOVER’s first round of clinical trials are failing. Will the next phase be better?

    RECOVER’s first round of clinical trials are failing. Will the next phase be better?

    The NIH studies found that Paxlovid, ivabradine, and computer games did not significantly improve symptoms of Long COVID. Further analysis that may help future research research has not yet been released.

get the latest long covid news

Processing…
Success! You're on the list.
SpotifyApple PodcastsPocketCastsAmazon MusiciHeartRadio